Published in Vaccine Weekly, October 10th, 2001
"The successful filing of an IND for our second clinical candidate represents a major milestone. We now have two clinical candidates based on our proprietary Tolerance Technology approach," said Steven B. Engle, La Jolla Pharmaceutical Company. "Like our Phase III drug candidate for lupus, LJP 1082 is designed to reduce the production of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly